Company Overview

Motus GI Holdings, Inc. is a medical technology company focused on improving visualization and procedural efficiency during gastrointestinal endoscopy procedures. The company operates within the healthcare technology and medical devices industries, with its primary commercial focus centered on technologies designed to enhance colonoscopy preparation and reduce procedural inefficiencies caused by inadequately cleansed colons. Its core product platform has been the Pure-Vu System, a device designed to enable intraprocedural cleansing of the colon during colonoscopy procedures.

The company’s primary revenue drivers have historically included sales and placements of the Pure-Vu System and related disposable components used in hospital and endoscopy settings. Motus GI has primarily targeted hospitals, ambulatory surgical centers, and gastroenterology providers, particularly in cases involving hospitalized patients where bowel preparation challenges can delay diagnosis or treatment. The company has positioned itself around procedural efficiency and improved visualization in difficult-to-cleanse colonoscopy cases. Motus GI was founded in Israel and later established operations in the United States, evolving from an early-stage medical device developer into a publicly traded healthcare technology company listed on Nasdaq under the ticker MOTS. Public filings indicate the company has faced ongoing commercialization and financing challenges common among emerging medical device firms.

Business Operations

Motus GI’s operations have primarily revolved around the commercialization and development of the Pure-Vu System and associated disposable technologies. The company has historically reported a single operating segment focused on gastrointestinal endoscopy technologies. Revenue generation has depended largely on product sales, leasing arrangements, and recurring disposable usage tied to procedures utilizing the Pure-Vu platform. Operations have included research and development, regulatory activities, manufacturing oversight, sales, and commercialization efforts directed primarily toward U.S. healthcare institutions.

The company has maintained operations in both the United States and Israel, with corporate functions and commercialization activities concentrated in the U.S. and portions of engineering and development historically connected to Israel. Motus GI has relied on third-party manufacturing relationships for aspects of production and supply chain management. Public disclosures have referenced collaborations with healthcare providers and clinical institutions for product evaluation and adoption, though publicly available information does not indicate the existence of major transformative joint ventures comparable to those of larger medical device companies. Data inconclusive based on available public sources regarding any currently active large-scale strategic partnerships beyond standard commercial and clinical relationships.

Strategic Position & Investments

Motus GI’s strategic direction has focused on expanding adoption of the Pure-Vu System within hospital-based gastroenterology procedures, particularly for patients with inadequate bowel preparation. The company has emphasized clinical utility, workflow efficiency, and potential reductions in repeat procedures or delayed care. Growth initiatives described in public filings and investor materials have included commercialization expansion, generation of clinical evidence, physician adoption programs, and efforts to secure broader market acceptance within gastroenterology practices and hospitals.

The company has also pursued financing activities and operational restructuring initiatives to support commercialization and ongoing operations. Public records indicate Motus GI has explored strategic alternatives and capital-raising efforts amid liquidity pressures. The company’s investment profile has remained concentrated on its core gastrointestinal endoscopy technology platform rather than diversified portfolio holdings. Available public disclosures do not identify major wholly owned operating subsidiaries with independent business lines beyond entities associated with the company’s core operations. Data inconclusive based on available public sources regarding significant acquisitions or broad portfolio investments outside its primary technology platform.

Geographic Footprint

Motus GI has maintained a primary commercial presence in the United States, which has represented its principal target market for commercialization activities and healthcare customer engagement. The company has also maintained operational and historical ties to Israel, where portions of its technology development and corporate origins are connected. Its headquarters operations have been associated with the United States, while engineering and legacy development activities have included Israeli operations.

The company’s market focus has largely centered on North American healthcare institutions, although public disclosures have indicated interest in broader international opportunities over time. Compared with larger multinational medical device companies, Motus GI’s international operational footprint has remained relatively limited. Data inconclusive based on available public sources regarding material revenue concentration outside the United States or substantial operational infrastructure across additional continents.

Leadership & Governance

Motus GI has operated under a traditional public-company governance structure led by executive management and a board of directors. The company’s leadership has emphasized commercialization of gastrointestinal procedural technologies, capital management, and clinical adoption strategies for the Pure-Vu System. Public communications and filings have consistently highlighted goals related to improving procedural outcomes, operational efficiency in endoscopy, and expanding hospital utilization of the company’s technology platform.

Key executives and leadership figures identified in public filings and corporate disclosures have included:

• Timothy Moran – Chief Executive Officer
• Andrew Taylor – Chief Financial Officer
• Mark Pomeranz, MD – Chief Medical Officer
• David B. Marcus – Chairman of the Board

Leadership and governance priorities described in public filings have included commercialization discipline, clinical validation, operational efficiency, and efforts to maintain regulatory compliance and access to capital markets as the company pursued broader adoption of its gastrointestinal technology platform.